在过去的二十年中，套细胞淋巴瘤 (MCL) 的一线治疗不断发展。然而，后续治疗对生存结果的影响尚未得到很好的表征。在这项研究中，我们调查了接受二线 (2 L) 治疗的复发/难治性 (R/R) MCL 患者的治疗模式和生存结果。 2002 年至 2015 年新诊断 MCL 的成年患者被纳入一项前瞻性队列研究。比较了 2003-2009 年（第 1 代）、2010-2014 年（第 2 代）和 2015-2021 年（第 3 代）接受 2 L 治疗的患者的临床特征、2 L 治疗细节和结果。 2L 治疗在各个时代都是异质的，并且随着时间的推移，2L 治疗的模式发生了实质性的转变。第 1-3 代的估计 2 年 EFS 率分别为 21% (95% CI, 13-35)、40% (95% CI, 30-53) 和 51% (95% CI, 37-68) ，第 1-3 代的 5 年 OS 率为 31% (95% CI, 21-45)、37% (95% CI, 27-50) 和 67% (95% CI, 54-83) ， 分别。这些结果为基于复发时代的 2 L 治疗演变的治疗模式提供了真实世界的证据。 2 L 治疗的变化与 EFS 和 OS 的改善相关，表明治疗进展与 R/R MCL 患者的预后改善相关。© 2023。作者。

Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003-2009 (Era 1), 2010-2014 (Era 2), and 2015-2021 (Era 3). 2 L treatment was heterogenous in all eras, and there was a substantial shift in the pattern of 2 L therapy over time. The estimated 2-year EFS rate was 21% (95% CI, 13-35), 40% (95% CI, 30-53), and 51% (95% CI, 37-68) in Era 1-3 respectively, and the 5-year OS rate was 31% (95% CI, 21-45), 37% (95% CI, 27-50), and 67% (95% CI, 54-83) in Era 1-3, respectively. These results provide real-world evidence on evolving treatment patterns of 2 L therapy based on the era of relapse. The changes in 2 L treatment correlated with improved EFS and OS, suggesting that treatment advances are associated with improved outcomes in patients with R/R MCL.© 2023. The Author(s).